Tellgen Revenue and Competitors

浦东新区,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Tellgen's estimated annual revenue is currently $5M per year.(i)
  • Tellgen's estimated revenue per employee is $251,000

Employee Data

  • Tellgen has 20 Employees.(i)
  • Tellgen grew their employee count by 0% last year.

Tellgen's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is Tellgen?

透景科技,流式荧光和多重检测专家! 上海透景生命科技股份有限公司(Tellgen Corporation, 简称透景科技)成立于2003年11月,座落在有“药谷”之称的浦东张江高科技园区,公司创始人为姚见儿。 透景科技最具特色的技术是流式荧光发光技术。该技术平台最重要的特点为多重高通量检测,即一次检测可以获得多达几十种上百种生物标志物的检测结果;同时,该技术平台的检测速度可高达每小时120-4000测试,是目前最高通量最快速度的检测方法。该技术的应用能大大提高检测的速度和效率。 透景科技目前累计获得50余项产品的注册证。方法学包括流式荧光平台、化学发光平台和荧光PCR平台。涉及肿瘤标志物、质控品、男性不育、宫颈癌筛查等。 透景科技共有肿瘤标志物定量检测试剂盒注册证25个,可检测肿瘤标志物种类多达18种,是国内肿瘤标志物项目较全的公司之一。透景科技目前主要采用两种方法学,一种为流式荧光发光法,该方法特点是可以实现多肿瘤标志物的并行定量检测,是为数不多的可实现多肿瘤标志物高通量检测的试剂盒。另外一种方法为化学发光法。

keywords:N/A

N/A

Total Funding

20

Number of Employees

$5M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Tellgen News

2022-04-13 - Molecular Diagnosis of Testicular Cancer Market to Witness ...

Some of the Major Key players profiled in the study are Tellgen, Sansure, Annoroad. Get PDF Sample Report + All Related Table and Graphs :.

2022-04-13 - Chest Cancer Molecular Diagnostics Market Is Expected to ...

... Influencing in this Market include:Roche, Qiagen, Illumina, Abbott, Oncotypeiq, BD, Tellgen, Genetech, Gpmedical, Zeesan, Sansure.

2022-04-06 - Cancer Antigen Market Research Insights with Upcoming ...

Tellgen corp. Labor diagnostika nord gmbh and cokg. Henso medical (hangzhou) co. Ltd. Gritstone oncology. Lee biosolutions. Shinjin medics

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.1M21-19%N/A
#2
$32.9M2061%N/A
#3
$42.1M264-4%N/A
#4
$189.2M932-15%N/A
#5
$799.2M1631-5%N/A